Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Boosted by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,975,655 shares of the company's stock after purchasing an additional 55,283 shares during the quarter. Vanguard Group Inc. owned 4.04% of Enliven Therapeutics worth $44,452,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter worth approximately $8,199,000. Geode Capital Management LLC increased its position in shares of Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after buying an additional 67,813 shares in the last quarter. Barclays PLC raised its stake in shares of Enliven Therapeutics by 295.8% during the 3rd quarter. Barclays PLC now owns 56,217 shares of the company's stock worth $1,435,000 after buying an additional 42,012 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Enliven Therapeutics by 107.0% in the 3rd quarter. Wellington Management Group LLP now owns 70,170 shares of the company's stock worth $1,792,000 after buying an additional 36,267 shares in the last quarter. Finally, State Street Corp grew its stake in Enliven Therapeutics by 2.9% in the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock valued at $19,051,000 after acquiring an additional 21,018 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Performance

Shares of ELVN traded up $0.04 during trading hours on Thursday, hitting $16.11. The stock had a trading volume of 35,408 shares, compared to its average volume of 261,979. The firm has a market cap of $789.50 million, a P/E ratio of -8.50 and a beta of 1.03. The company's fifty day simple moving average is $19.97 and its 200 day simple moving average is $23.14. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Monday, April 7th. The shares were sold at an average price of $18.04, for a total transaction of $120,272.68. Following the transaction, the chief operating officer now directly owns 316,643 shares in the company, valued at $5,712,239.72. This represents a 2.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the company's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $280,670. This trade represents a 20.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,751 shares of company stock worth $1,178,263. 29.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.